Lung Cancer: Targeted Therapy in 2025
Lung cancer treatment has changed in the last twenty years since the discovery of EGFR mutations. In this article, we will review the current state of the art for non-small cell lung cancer (NSCLC) actionable genomic alterations (AGA). AGAs are mostly found in lung adenocarcinomas, a subtype of non-...
Saved in:
| Main Authors: | Nicole Bouchard, Nathalie Daaboul |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/3/146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Autophagy and lung cancer therapy: targeted drug development and new emerging technology
by: Ming Zhang, et al.
Published: (2025-04-01) -
Effects of microRNA on the growth and targeted therapy response on lung cancer
by: Mengchen Zhu, et al.
Published: (2024-12-01) -
Molecular Diagnosis of Lung Cancer
by: Savelina Popovska, et al.
Published: (2018-03-01) -
COX‐2 in lung cancer: Mechanisms, development, and targeted therapies
by: Xueqi Liu, et al.
Published: (2024-12-01) -
Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer
by: Hidenori Kage
Published: (2025-07-01)